Reported about 9 hours ago
Mallinckrodt and Endo, both drugmakers with a history of bankruptcy and involvement in opioid litigation, are set to merge in a deal worth nearly $7 billion. Endo shareholders will receive $80 million in cash and retain 49.9% ownership of the new entity, while Mallinckrodt shareholders will hold the remainder. This merger aims to create a larger company with combined revenues of $3.6 billion in 2025, uniting their branded and generic drug businesses while forming a separate entity for some of their generic operations. The merger is expected to close in the second half of 2025.
Source: YAHOO